Arkolith/Insider Trading/NAMS/Form 4

Kastelein Johannes Jacob Pieter

Chief Scientific Officer, DirectorNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Feb 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.6M
Net Open-Market Flow
-$1.6M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 20, 2026Sell(S)31K$35.46$1.1M54K
Feb 20, 2026Sell(S)15K$35.00$514K84K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-067260) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML